Evidence map›Paper›PMID 31438858›Full record

ArticleBMC cardiovascular disorders2019

Randomised, double-blind, placebo-controlled clinical trial for evaluating the efficacy of intracoronary injection of autologous bone marrow mononuclear cells in the improvement of the ventricular function in patients with idiopathic dilated myocardiopathy: a study protocol.

Miguel Romero, José Suárez-de-Lezo, Concha Herrera, Manuel Pan, José López-Aguilera, José Suárez-de-Lezo, Flor Baeza-Garzón, Francisco Javier Hidalgo-Lesmes, Olga Fernández-López, Juliana Martínez-Atienza and 9 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in BMC cardiovascular disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02033278 (Multicenter Phase IIb Clinical Trial, Double-blind, Randomized, Controlled Placebo for to Assess the Efficacy of Intracoronary Infusion of Autologous Adult Stem Cells Mononuclear Marrow Unexpanded on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02033278 phase2terminatednot on this map

Multicenter Phase IIb Clinical Trial, Double-blind, Randomized, Controlled Placebo for to Assess the Efficacy of Intracoronary Infusion of Autologous Adult Stem Cells Mononuclear Marrow Unexpanded on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.

TypeinterventionalSponsorAndalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y SaludRan2014 to 2020Enrolled27ConditionsIdiopathic Dilated CardiomyopathyArmsInfusion of autologous mononuclear bone marrow cells, Placebo infusion
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Miguel RomeroCardiology Unit, Reina Sofía University Hospital, Córdoba, Spain.
José Suárez-de-LezoCardiology Unit, Reina Sofía University Hospital, Córdoba, Spain.
Concha HerreraCell Production Unit, Reina Sofía University Hospital, Córdoba, Spain.
Manuel PanCardiology Unit, Reina Sofía University Hospital, Córdoba, Spain.
José López-AguileraCardiology Unit, Reina Sofía University Hospital, Córdoba, Spain.
José Suárez-de-LezoCardiology Unit, Reina Sofía University Hospital, Córdoba, Spain.
Flor Baeza-GarzónCardiology Unit, Reina Sofía University Hospital, Córdoba, Spain.
Francisco Javier Hidalgo-LesmesCardiology Unit, Reina Sofía University Hospital, Córdoba, Spain.
Olga Fernández-LópezAndalusian Initiative for Advanced Therapies, Andalusian Public Foundation Progress and Health - Junta de Andalucía, 41006, Esquina Avda. Hytasa, Seville, Spain.
Juliana Martínez-AtienzaAndalusian Initiative for Advanced Therapies, Andalusian Public Foundation Progress and Health - Junta de Andalucía, 41006, Esquina Avda. Hytasa, Seville, Spain. juliana.martinez@juntadeandalucia.es.ORCID 0000-0002-0391-5180
Eva CebriánCardiology Unit, Reina Sofía University Hospital, Córdoba, Spain.
Vanesa Martín-PalancoCell Production Unit, Reina Sofía University Hospital, Córdoba, Spain.
Rosario Jiménez-MorenoCell Production Unit, Reina Sofía University Hospital, Córdoba, Spain.
Rosario Gutiérrez-FernándezCell Production Unit, Reina Sofía University Hospital, Córdoba, Spain.
Sonia NoguerasCell Production Unit, Reina Sofía University Hospital, Córdoba, Spain.
Maria Dolores CarmonaCell Production Unit, Reina Sofía University Hospital, Córdoba, Spain.
Soledad OjedaCardiology Unit, Reina Sofía University Hospital, Córdoba, Spain.
Natividad CuendeAndalusian Initiative for Advanced Therapies, Andalusian Public Foundation Progress and Health - Junta de Andalucía, 41006, Esquina Avda. Hytasa, Seville, Spain.
Rosario MataAndalusian Initiative for Advanced Therapies, Andalusian Public Foundation Progress and Health - Junta de Andalucía, 41006, Esquina Avda. Hytasa, Seville, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCellular therapies have been increasingly applied to diverse human diseases. Intracoronary infusion of bone marrow-derived mononuclear cells (BMMNC) has demonstrated to improve ventricular function after acute myocardial infarction. However, less information is available about the role of BMMNC therapy for the treatment of dilated myocardiopathies (DCs) of non-ischemic origin. This article presents the methodological description of a study aimed at investigating the efficacy of intracoronary injection of autologous BMMNCs in the improvement of the ventricular function of patients with DC.

methodsThis randomised, placebo-controlled, double-blinded phase IIb clinical trial compares the improvement on ventricular function (measured by the changes on the ejection fraction) of patients receiving the conventional treatment for DC in combination with a single dose of an intracoronary infusion of BMMNCs, with the functional recovery of patients receiving placebo plus conventional treatment. Patients assigned to both treatment groups are monitored for 24 months. This clinical trial is powered enough to detect a change in Left Ventricular Ejection Fraction (LVEF) equal to or greater than 9%, although an interim analysis is planned to re-calculate sample size. DISCUSSION: The study protocol was approved by the Andalusian Coordinating Ethics Committee for Biomedical Research (Comité Coordinador de Ética en Investigación Biomédica de Andalucia), the Spanish Medicines and Medical Devices Agency (Agencia Española de Medicamentos y Productos Sanitarios), and is registered at the EU Clinical Trials Register (EudraCT: 2013-002015-98). The publication of the trial results in scientific journals will be performed in accordance with the applicable regulations and guidelines to clinical trials.

trial registrationClinicalTrials.gov Identifier NCT02033278 (First Posted January 10, 2014): https://clinicaltrials.gov/ct2/show/NCT02033278 ; EudraCT number: 2013-002015-98, EU CT Register: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002015-98 . Trial results will also be published according to the CONSORT statement at conferences and reported peer-reviewed journals.

Indexed as

Bone Marrow TransplantationVentricular Function, LeftAdolescentAdultAgedCardiomyopathy, DilatedClinical Trials, Phase II as TopicDouble-Blind MethodFemaleHumansMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicRecovery of FunctionSpainBone marrow mononuclear cellsCell therapyDilated myocardiopathyRandomized controlled trial

Identifiers

PMID31438858
PMCPMC6704590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.